1. TLR7 Agonist Suppresses Group 2 Innate Lymphoid Cell-mediated Inflammation via IL-27-Producing Interstitial Macrophages.
- Author
-
Okuzumi S, Miyata J, Kabata H, Mochimaru T, Kagawa S, Masaki K, Irie M, Morita H, and Fukunaga K
- Subjects
- Animals, Asthma genetics, Asthma immunology, Asthma pathology, Chemokine CCL17 genetics, Chemokine CCL17 immunology, Chemokine CCL24 genetics, Chemokine CCL24 immunology, Eosinophils immunology, Eosinophils pathology, Immunity, Innate genetics, Inflammation genetics, Inflammation immunology, Interleukin-33 genetics, Interleukin-33 immunology, Interleukins genetics, Lung pathology, Lymphocytes pathology, Macrophages pathology, Membrane Glycoproteins genetics, Membrane Glycoproteins immunology, Mice, Mice, Inbred BALB C, Mice, Knockout, Receptors, Interleukin deficiency, Receptors, Interleukin immunology, Signal Transduction genetics, Signal Transduction immunology, Toll-Like Receptor 7 genetics, Toll-Like Receptor 7 immunology, Imidazoles pharmacology, Immunity, Innate drug effects, Interleukins immunology, Lung immunology, Lymphocytes immunology, Macrophages immunology, Membrane Glycoproteins agonists, Signal Transduction drug effects, Toll-Like Receptor 7 agonists
- Abstract
Group 2 innate lymphoid cells (ILC2s) play an important role in the pathophysiology of asthma via the robust production of type 2 cytokines. Recent studies have demonstrated that TLR7 (Toll-like receptor 7) signaling skews toward a type 1 inflammatory response in asthma, which may lead to the development of novel treatment strategies. However, the effect of TLR7 signaling on ILC2-dependent nonallergic eosinophilic inflammation remains unclear. In this study, we investigated the effects of R848, a TLR7 agonist, in a mouse model of IL-33-induced eosinophilic airway inflammation. Intranasal administration of R848 decreased infiltration of airway eosinophils and ILC2s, mucus production in epithelial cells, and type 2 cytokine production. Flow cytometric analysis identified an increased number of interstitial macrophages (IMs) expressing a high level of TLR7 in the lung upon IL-33 stimulation. IL-33-induced IMs also expressed high levels of alternatively activated (M2)-type genes and chemokines (CCL17 and CCL24). However, R848 stimulation modified these gene expressions and elicited the production of IL-27. Coculture experiments revealed that IL-33-induced IMs directly suppressed ILC2 activation in response to R848. In addition, the inhibitory effects of R848 on ILC2-induced type 2 inflammation were defective in WSX-1-deficient mice lacking the IL-27 receptor. Taken together, these findings indicate that R848 stimulates IL-33-induced IMs to suppress ILC2-mediated type 2 airway inflammation via IL-27. These findings highlight the therapeutic potential of TLR7 agonists and/or IL-27 cascades in nonallergic asthma.
- Published
- 2021
- Full Text
- View/download PDF